Get the Stockscreener App
3.3299
1.83%
0.0599
After Hours:
3.33
0.0001
+0.00%
Opthea Limited Adr stock is traded at $3.3299, with a volume of 7,803.
It is up +1.83% in the last 24 hours and down -20.15% over the past month.
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.
See More
Previous Close:
$3.27
Open:
$3.34
24h Volume:
7,803
Relative Volume:
0.26
Market Cap:
$503.21M
Revenue:
$117.10K
Net Income/Loss:
$-161.61M
P/E Ratio:
-1.3713
EPS:
-2.4283
Net Cash Flow:
-
1W Performance:
+1.52%
1M Performance:
-20.15%
6M Performance:
+4.06%
1Y Performance:
+50.67%
1-Day Range:
$3.31
$3.34
1-Week Range:
$3.09
$3.34
52-Week Range:
$1.79
$5.45
Opthea Limited Adr Stock (OPT) Company Profile
Compare OPT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OPT
Opthea Limited Adr
|
3.3299 | 503.21M | 117.10K | -161.61M | 0 | -2.4283 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Opthea Limited Adr Stock (OPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-08-22 | Initiated | H.C. Wainwright | Buy |
| Apr-26-22 | Initiated | SVB Leerink | Outperform |
| Nov-17-20 | Initiated | Citigroup | Buy |
| Nov-11-20 | Initiated | Oppenheimer | Outperform |
| Nov-11-20 | Initiated | SVB Leerink | Outperform |
| Nov-11-20 | Initiated | Truist | Buy |
View All
Opthea Limited Adr Stock (OPT) Latest News
Opthea's Wet AMD Program to be Featured at FLORetina 2024 - The Manila Times
Opthea Highlights Innovative Wet AMD Therapy - TipRanks
Opthea to Participate in Citi 2024 Global Healthcare Conference - Yahoo Finance
Opthea Limited to Engage Investors at Healthcare Conference - TipRanks
Opthea Limited Targets AMD Market with Sozinibercept - TipRanks
Opthea Appoints Kathy Connell to Board of Directors - The Manila Times
Opthea Appoints Kathy Connell to Board of Directors - GlobeNewswire Inc.
Opthea : Chairman’s Address to the 2024 Annual General Meeting Form 6 K - Marketscreener.com
Opthea Limited Announces Board Changes - Marketscreener.com
Opthea's Wet AMD Program Featured at Ophthalmology Events - The Manila Times
Opthea’s Wet AMD Program Featured at Ophthalmology Events - Yahoo Finance Australia
Opthea (NASDAQ:OPT) Shares Up 1.7% – What’s Next? - Defense World
Opthea to Participate in November Investor Conferences - The Manila Times
Opthea : UPDATE Opthea to Participate in November Investor Conferences Form 6 K - Marketscreener.com
Opthea Limited Strengthens Leadership and Advances AMD Treatment - TipRanks
FY2025 EPS Estimates for Opthea Lifted by Leerink Partnrs - Defense World
OPTOpthea Limited American Depositary Shares Latest Stock News & Market Updates - StockTitan
Is Opthea Limited (OPT) the Penny Stock with the Biggest Upside Potential According to Analysts? - Insider Monkey
Opthea Files Notice of Annual General Meeting - The Manila Times
Opthea Ltd stock soars to 52-week high, touches $4.95 - Investing.com India
Opthea Ltd stock soars to 52-week high, touches $4.95 By Investing.com - Investing.com South Africa
Opthea Wet AMD Program to be Presented at Innovate Retina - The Manila Times
Opthea Appoints Chief Medical Officer and Chief Financial Officer as Company Prepares for Phase 3 Topline Data Readouts in 2025 - The Manila Times
Opthea Limited Announces Chief Financial Officer Changes - Marketscreener.com
Opthea to Participate in the UBS Virtual Ophthalmology Day 2024 - The Manila Times
Opthea Advances Retinal Disease Treatments - TipRanks
Opthea Advances nAMD Treatment with Sozinibercept - TipRanks
Opthea Joins the S&P/ASX 300 Index - StockTitan
Opthea Limited (NASDAQ:OPT) Shares Sold by Victory Capital Management Inc. - Defense World
EX-99.1 - SEC.gov
Opthea Advances Toward Sozinibercept Commercialization - TipRanks
Opthea’s Sozinibercept Eyes Breakthrough in AMD Therapy - TipRanks
FY2025 EPS Estimates for Opthea Limited Boosted by HC Wainwright (NASDAQ:OPT) - Defense World
Research Analysts Set Expectations for Opthea Limited’s FY2029 Earnings (NASDAQ:OPT) - Defense World
Opthea Prepares for Phase 3 Results with Leadership Revamp - TipRanks
Opthea (NASDAQ:OPT) Given New $12.00 Price Target at HC Wainwright - Defense World
Opthea Limited Showcases Innovations at Investor Conferences - TipRanks
Opthea Limited: Revenues Up, Losses Widen - TipRanks
Opthea Reports Full-Year Financial Results and Business Updates - Morningstar
Opthea to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference, August 15, 2024 - Morningstar
Opthea Limited Showcases at Ophthalmology Event - TipRanks
'Blockbuster opportunity': This speculative ASX stock could rise 70% - The Motley Fool Australia
Opthea forms global medical advisory board for retinal diseases - Investing.com India
Opthea Welcomes International Retina Thought Leaders to Join Its Medical Advisory Board - StockTitan
Why Atturra, Bravura, Core Lithium, and Opthea shares are racing higher today - The Motley Fool
Opthea’s Sozinibercept Shows Promise for Wet AMD - TipRanks
Opthea Announces Publication on VEGF-C and D Signaling Pathways as Potential Targets for Treatment of Wet AMD - StockTitan
Opthea (NASDAQ:OPT) Shares Down 0.8% - Defense World
Opthea Data for OPT-302 in Patients with Polypoidal Choroidal Vasculopathy (PCV) Presented at Angiogenesis 2022 - The Globe and Mail
Opthea To Present at SVB Leerink Global Healthcare Conference - The Globe and Mail
Opthea strengthens its Board of Directors - Quantisnow
Opthea Limited Adr Stock (OPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):